论文部分内容阅读
目的对比联合应用头孢曲松及阿奇霉素与单用头孢曲松治疗社区获得性肺炎的疗效和安全性。方法将104例社区获得性肺炎患者随机分成头孢曲松联合阿奇霉素组(治疗组)和单用头孢曲松组(对照组),治疗8天后,观察两组的临床疗效和不良反应。结果治疗组52例,痊愈37例(71.1%),好转13例(25.0%),总有效率96.1%,不良反应发生率7.6%;对照组52例,痊愈26例(50%),好转9例(17.3%),总有效率67.3%,不良反应发生率3.8%。两组临床疗效有统计学差异(P<0.05),不良反应无统计学差异(P>0.05)。结论头孢曲松联合应用阿奇霉素治疗社区获得性肺炎临床疗效优于单用头孢曲松,是社区获得性肺炎初始经验治疗的良好选择。
Objective To compare the efficacy and safety of ceftriaxone, azithromycin and ceftriaxone alone in the treatment of community-acquired pneumonia. Methods 104 patients with community-acquired pneumonia were randomly divided into ceftriaxone group (treatment group) and ceftriaxone group (control group). After 8 days of treatment, the clinical efficacy and adverse reactions of the two groups were observed. Results In the treatment group, 52 cases were cured, 37 cases were cured (71.1%), 13 cases (25.0%) were improved, the total effective rate was 96.1%, and the incidence of adverse reactions was 7.6%. In the control group, 52 cases were cured (26%, 50% Cases (17.3%), the total effective rate 67.3%, the incidence of adverse reactions 3.8%. There was significant difference between the two groups (P <0.05) and no significant difference (P> 0.05). Conclusion The clinical efficacy of ceftriaxone combined with azithromycin in the treatment of community-acquired pneumonia is better than that of ceftriaxone alone, which is a good choice for initial experience-based treatment of community-acquired pneumonia.